Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04683718
Other study ID # BENEFIT-03
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 20, 2021
Est. completion date February 2026

Study information

Verified date October 2023
Source Biotronik, Inc.
Contact Justin Michalski
Phone (503)927-7230
Email benefit03@biotronik.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The BENEFIT-03 Clinical Study is a first in human, prospective, multi-center, single-arm, interventional feasibility study to be conducted in Australia. The purpose of the BENEFIT-03 study is to collect initial safety and effectiveness data on the BIOTRONIK Prosper SCS (Spinal Cord Stimulation) System with HomeStream Remote Management. Enrolled participants will complete a SCS trial period per the standard of care utilizing the BIOTRONIK Resilience percutaneous SCS trial leads and the BIOTRONIK Prospera External Pulse Generator (EPG). Following a successful trial period, participants will be implanted with a permanent BIOTRONIK Prospera Implantable Pulse Generator (IPG). Implanted participants will be followed for 24 months post-implant with in-office visits and remote management visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date February 2026
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: - Currently indicated for SCS therapy for the treatment of low back and/or leg pain - Planned permanent implant of BIOTRONIK's Prospera SCS System with HomeStream Remote Management - Planned placement of two BIOTRONIK Resilience SCS trial leads - Documented scores of = 60 mm out of 100 mm on the Visual Analog Scale (VAS) for both overall pain intensity and pain intensity in the index area of pain, assessed at the time of enrollment - Willing and able to comply with all study requirements, including all required procedures, phone and/or video calls, and study visits - Age greater than or equal to 18 years and less than 80 years - Able to understand the nature of the study and provide written informed consent - Able to read, understand, and speak English - Patient's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation - Oswestry Disability Index (ODI) score of 41 to 80 out of 100 - Passed psychological evaluation - For diabetic patients: minimum of one HbA1c test within the last 6 months, with most recent result = 8.0% Exclusion Criteria: - Any contraindication for SCS therapy - Patients with an implanted pacemaker, defibrillator, or any other medical contraindication for SCS therapy - Currently implanted with an infusion pump or any implantable neurostimulator device - Previously implanted with a neurostimulation system or prior participation in a trial period for a neurostimulation system - Currently enrolled in any investigational device or drug trial for the management of chronic pain - Patients who have undergone spinal surgery within 12 months prior to enrollment - Patients currently involved in an active WorkCover insurance claim and/or active litigation related to injury associated with indication for SCS - Patients with a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency (other than prescribed) in the 6 months prior to enrollment - Patients currently displaying opioid-seeking behavior - Presence of any life-threatening, underlying illness - Life expectancy less than 1 year - Patients reporting pregnancy at the time of enrollment or intending to become pregnant during the 2-year study duration - Patients with opioid dosages > 120 morphine milligram equivalents (MME) per day - Patients with poor compliance for pain management regimen - Patients with a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the investigator - Patients with pain originating from peripheral vascular disease - Current diagnosis of a coagulation disorder or bleeding diathesis - Patients with a diagnosis of severe thoracic scoliosis that is likely to preclude SCS lead placement - Patients who are immunocompromised and/or at high risk for infection - Patients with a documented history of allergic response or sensitivity to material(s) required for the study (e.g. adhesives, titanium, silicone, etc.) At the conclusion of the trial period, the absence of the following exclusion criteria should be confirmed before proceeding with the permanent Prospera SCS System implant: - Reduction in overall pain of less than 50% from baseline, assessed using VAS - Unsuccessful trial period as otherwise determined by the investigator - Determined by the investigator to be a poor candidate for permanent Prospera SCS System implant per standard of care (e.g. due to infection, non-compliance with pain medication regimen, paresis, clumsiness, numbness, and other) Additionally, pre-operative screening for staphylococcus aureus (MRSA/MSSA) must be conducted after the SCS trial period and prior to implantation of the permanent device.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management
The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.

Locations

Country Name City State
Australia Genesis Research Services Broadmeadow New South Wales
Australia Monash Clinical Research Clayton Victoria
Australia Australian Medical Research Hurstville New South Wales
Australia Sunshine Coast Clinical Research Noosa Heads Queensland
Australia Sydney Pain Research Centre Wahroonga New South Wales

Sponsors (3)

Lead Sponsor Collaborator
Biotronik, Inc. Biotronik Australia Pty Ltd., BIOTRONIK Neuro

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Responder Rate to the BIOTRONIK Prospera SCS System Therapy The purpose of primary endpoint 1 is to evaluate the overall responder rate of participants to the BIOTRONIK SCS Therapy at the 6-month follow-up interval. To be classified as a responder, a participant must achieve a reduction in overall pain intensity of at least a 50% from baseline, assessed using the Visual Analog Scale (VAS). 6 months post-implant
Primary Primary Safety Information on the BIOTRONIK Prospera SCS System The purpose of primary endpoint 2 is to collect primary safety information on the BIOTRONIK Prospera SCS System from permanent implant through the 6-month follow-up interval. 6 months post-implant
See also
  Status Clinical Trial Phase
Recruiting NCT05963451 - Brain, Psychological and Epigenetic Determinants for Optimizing the Treatment of Chronic Low Back Pain
Completed NCT04283370 - A Study Protocol Comparing a Home Rehabilitation Program Versus e-Health Program in Low Back Pain N/A
Completed NCT04824547 - Evaluation of Long-Term Continuity of Exercises in Low Back Pain Individuals N/A
Completed NCT04046419 - In Turkish Version "Health Care Providers and Impairment Relationship Scale (HC-PAIRS)"
Completed NCT04399772 - COgNitive FuncTional Therapy+ for Chronic Low Back paIn N/A
Recruiting NCT05780021 - Motivational Support Program in Chronic Low Back Pain After Multidisciplinary Functional Rehabilitation N/A
Completed NCT04555278 - Combining Non-invasive Brain Stimulation and Exercise to Treat Low Back Pain N/A
Completed NCT04530071 - Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain Phase 1/Phase 2
Not yet recruiting NCT06347328 - The Benefits of Posterior Joint Infiltration in Chronic Low Back Pain N/A
Not yet recruiting NCT06080464 - Clinician Satisfaction With the VERABANDâ„¢ N/A
Not yet recruiting NCT04940715 - Efficacy of Passive Joint Mobilization vs Mobilization With Movement on Pain Processing in Patients With Chronic Low Back Pain N/A
Recruiting NCT05724160 - Using Non-Weightbearing Stationary Elliptical Machines for Patients With Chronic Low Back Pain N/A
Recruiting NCT06030128 - Core Stabilization Exercise Therapy in Chronic Lower Back Back Management in Community Dwelling Older Adults N/A
Recruiting NCT05846087 - Mobile App-delivered Sleep Therapy (SleepFix) for Individuals With Chronic Low Back Pain and Insomnia N/A
Active, not recruiting NCT05396014 - The BEST Trial: Biomarkers for Evaluating Spine Treatments Phase 4
Active, not recruiting NCT06140862 - Ankle Spine Syndrome "RAFFET Syndrome II N/A
Completed NCT05512338 - Motivation and Adherence to Exercise Recommendations N/A
Recruiting NCT05021146 - Essential Oil for Chronic Low Back Pain N/A
Completed NCT05120921 - Osteopathic Single CAse Research for Patients With Chronic Low Back Pain N/A
Completed NCT05690178 - Deep Tissue Massage in Office Workers With Chronic Low Back Pain N/A